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SUMMARY

Powassan virus (POWV) is an emerging tick-transmitted flavivirus that circulates in North America
and Russia. Up to 5% of deer ticks now test positive
for POWV in certain regions of the northern United
States. Although POWV infections cause life-threatening encephalitis, there is no vaccine or countermeasure available for prevention or treatment. Here,
we developed a lipid nanoparticle (LNP)-encapsulated modified mRNA vaccine encoding the POWV
prM and E genes and demonstrated its immunogenicity and efficacy in mice following immunization
with one or two doses. The POWV mRNA vaccine
induced high titers of neutralizing antibody and sterilizing immunity against lethal challenge with different
POWV strains. The mRNA vaccine also induced
cross-neutralizing antibodies against multiple other
tick-borne flaviviruses and protected mice against
the distantly related Langat virus. These data demonstrate the utility of the LNP-mRNA vaccine platform
for the development of vaccines with protective activity against multiple flaviviruses.
INTRODUCTION
Powassan virus (POWV) is a tick-borne flavivirus (TBFV) that
was first described following its isolation from the brain of a
child who died of encephalitis in Powassan, Ontario, in 1958
(McLean and Donohue, 1959). Human cases of POWV have
been reported in the United States, Canada, and Russia (reviewed in Ebel, 2010; Hermance and Thangamani, 2017).
Though POWV infections are relatively rare, they can cause severe or even fatal neuroinvasive disease, including encephalitis,
meningoencephalitis, and meningitis. Approximately 10% of
neuroinvasive POWV cases are fatal, and 50% of survivors
suffer long-term neurological sequelae (Ebel, 2010; Hermance

and Thangamani, 2017). Unfortunately, POWV is emerging;
increasing numbers of cases have been diagnosed in the United
States over the past decade (Hermance and Thangamani, 2017;
Krow-Lucal et al., 2018), and up to 5% of Ixodes scapularis ticks
isolated in parts of New York, Connecticut, and Wisconsin now
test positive for POWV (Aliota et al., 2014; Anderson and Armstrong, 2012; Knox et al., 2017).
Two genetic lineages of POWV circulate in North America,
lineage I and lineage II (also called deer-tick virus [DTV]),
although they are serologically and clinically indistinguishable
and share at least 96% amino acid identity in their envelope (E)
proteins (Ebel et al., 2001). POWV lineage I strains are predominantly maintained in Ixodes cookei ticks and include isolates
from New York and Canada, whereas lineage II strains are found
in Ixodes scapularis deer ticks and include strains from regions
infested by these ticks (Ebel et al., 2001). Because deer ticks
are more aggressive at biting humans, lineage II viruses may
have greater epidemic potential. Although POWV has been
found predominantly in north-central and northeastern parts of
the United States in Ixodes species ticks, POWV also has been
isolated from Dermacentor andersoni ticks in Colorado (Thomas
et al., 1960), indicating the vector and geographical range may
be larger than previously estimated.
The TBFVs are divided into three groups: the mammalian
group, the seabird group, and the Kadam virus group (Grard
et al., 2007). The mammalian TBFV group includes POWV and
several other human pathogens, including tick-borne encephalitis virus (TBEV), Omsk hemorrhagic fever virus (OHFV), Kyasanur
forest disease virus (KFDV), and Alkhurma hemorrhagic fever virus (AHFV). Within their E proteins, the mammalian TBFV group
shares R70% amino acid identity but only about 54%–60%
identity with seabird TBFVs. One exception is Gadgets Gully virus (GGYV), which is more closely related to the mammalian
TBFVs even though it causes infection of seabirds (Grard et al.,
2007). Vaccines have been developed against several mammalian TBFVs, although only TBEV vaccines have proven efficacy
(Ishikawa et al., 2014). TBEV vaccines induce antibodies capable
of neutralizing closely related TBFVs, including OHFV, KFDV,
and AHFV (McAuley et al., 2017). However, TBEV immune sera
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Figure 1. Lineage I and II POWV Strains Cause Lethal Disease in Adult Mice
(A–C) C57BL/6 mice were inoculated via subcutaneous inoculation in the footpad with 102 FFU of POWV lineage I LB at 7 weeks (n = 14) or 14 weeks (n = 15) of
age. Mice were monitored for (A) mortality, (B) weight loss, and (C) clinical disease for 21 days.
(D–F) C57BL/6 mice were inoculated subcutaneously at 7 weeks (n = 14) or 14 weeks (n = 10) of age with 102 FFU of POWV Spooner or at 14 weeks of age after
treatment with 0.5 mg of anti-Ifnar1 mAb administered via intraperitoneal one day before inoculation with POWV lineage II Spooner (n = 15). Mice were monitored
for (D) mortality, (E) weight change, and (F) clinical disease for 21 days.
(B and E) Error bars represent SEM. Data were collected from two (Spooner infection of 7-week-old mice) or three (all other data) independent experiments.

had limited cross-neutralizing activity against the more distantly
related POWV. No approved vaccines for POWV exist.
The lack of a POWV-specific vaccine, limited induction of
cross-neutralizing antibodies by other TBFV vaccines, and
epidemic potential for POWV prompted us to design a vaccine
and test its immunogenicity and efficacy. We selected a vaccine
platform that we developed for a distantly related flavivirus, Zika
virus (ZIKV): a lipid nanoparticle (LNP)-encapsulated modified
mRNA encoding the structural premembrane (prM) and E protein
genes (Richner et al., 2017a). Co-expression of the flavivirus
structural proteins prM and E results in the secretion of subviral
particles (SVPs) that share many functional and antigenic features with infectious virions and elicit neutralizing antibodies.
SVPs are heterogeneous in size and likely display E proteins in
distinct chemical environments, with the potential to affect
epitope display (Allison et al., 1995; Heinz et al., 1995; Kiermayr
et al., 2009; Konishi and Fujii, 2002; Konishi et al., 1992). In addition to selecting the POWV prM-E structural gene components,
we used an mRNA platform, because some modified mRNA
have been reported to enhance follicular helper T cell and
germinal center B cell responses that are essential for inducing
memory B cells and durable levels of neutralizing antibody (Pardi
et al., 2018).
Here, we describe an LNP-encapsulated modified mRNA vaccine encoding the prM-E of POWV that induces a potent neutralizing antibody response in mice and protects against lethal viral

challenge by strains of both POWV lineages. Furthermore, the
POWV mRNA vaccine induced cross-neutralization antibody titers against other TBFVs and conferred protection against disease following challenge of mice with the distantly related Langat
virus (LGTV).
RESULTS
A Lethal Model of POWV Infection in Adult Mice
In planning for vaccine efficacy studies, we developed challenge
models of POWV infection in adult mice. Although others have
described murine models of POWV infection, these have been
in juvenile mice (4–5 weeks old), which are not ideal for experiments requiring iterative immunization and resting periods
(Hermance and Thangamani, 2015; Holbrook et al., 2005; Mlera
et al., 2017; Santos et al., 2016; Wang et al., 2013). Accordingly,
we tested the ability of two POWV strains, LB (a lineage I strain)
and Spooner (a lineage II DTV strain) to cause morbidity and
mortality in wild-type (WT) C57BL/6 mice at 7 or 14 weeks of
age. Following subcutaneous inoculation of 102 focus-forming
units (FFU) of POWV LB, lethal infection ensued in 93% of 7and 14-week-old mice, with a mean time to death of 8.6 and
9.5 days post-infection (dpi), respectively (Figure 1A). All mice
inoculated with POWV LB lost approximately 15%–25% of their
body weight (Figure 1B). POWV LB-infected mice exhibited
ruffled fur, hunched posture, lethargy, and partial paralysis,
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Figure 2. POWV mRNA LNP Vaccine Induces High Levels of Neutralizing Antibody in Mice
(A) Scheme of the two-dose POWV Spooner mRNA LNP vaccination schedule.
(B–H) Serum samples collected pre- and post-boost were assayed for neutralization potency by an RVP-based assay using a lineage II POWV strain (P0375) and
Raji-SIGNR cells (n = 20 for JEVsig and placebo; n = 19 for POWVsig).
(B) The reciprocal neutralization titers (EC50 values) are shown. Bars represent median values. Statistical significance was determined using an ANOVA followed
by Tukey’s multiple comparisons test (ns, not significant; *p < 0.05; ****p < 0.0001).
(C–H) Representative dose response curves are shown for each vaccine and time point. The mean resistant fraction (RF) ± SEM is indicated on each panel. Error bars
represent ± SEM from two technical replicates. Serum samples were collected over four independent experiments and assayed once each for neutralization potency.
See also Figure S1.

although 50% of mice did not exhibit these signs before death
(Figure 1C). In comparison, POWV Spooner resulted in lower
mortality rates; 57% and 60% of 7- and 14-week-old mice succumbed to infection with mean times to death of 13.0 and
12.7 days, respectively (Figure 1D). Because of the partial
lethality caused by POWV Spooner in WT mice, we created a
more susceptible host by transiently blocking type I interferon
(IFN) signaling with an anti-IFN receptor (Ifnar1) monoclonal antibody (mAb), MAR1-5A3 (Sheehan et al., 2006). When 0.5 mg of
anti-Ifnar1 mAb was administered one day before infection,
POWV Spooner resulted in 100% lethality, with a mean time to
death of 9.7 days (Figure 1D). Whereas POWV Spooner-infected
WT mice typically displayed 15%–20% body weight loss, infected mice treated with anti-Ifnar1 mAb sustained greater
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weight loss of 30% (Figure 1E). Most POWV Spooner-infected
WT mice (70%–85%) displayed ruffled fur, hunched posture, and
lethargy, with a minority developing limb paralysis (Figure 1F). In
comparison, anti-Ifnar1 mAb-treated, POWV Spooner-infected
mice uniformly displayed signs of morbidity before death.
An mRNA Vaccine against POWV Induces High Levels of
Neutralizing Antibody in Mice
Having developed lethal challenge models in older mice, we engineered a LNP-encapsulated modified mRNA vaccine against
POWV that was based on a prM-E construct developed for
ZIKV (Richner et al., 2017a, 2017b). We designed a base-modified
mRNA encoding the prM and E genes of POWV Spooner that was
preceded by the prM signal sequence of POWV (POWVsig) or

Figure 3. POWV mRNA LNP Vaccines Induce Protective Immunity against Lineage I and II POWV Strains
(A–F) C57BL/6 mice receiving two doses of POWVsig or JEVsig vaccines or a placebo were challenged 4 weeks after the second dose with 102 FFU of (A–C) POWV
lineage II strain Spooner (following anti-Ifnar1 mAb treatment) (n = 10 per group) or (D–F) POWV lineage I strain LB (n = 10 for JEVsig and placebo; n = 9 for
POWVsig).
(G–I) Serum samples were collected from mice that received two doses of POWVsig or a placebo and passively transferred to naive C57BL/6 mice one day before
challenge with 102 FFU POWV LB (n = 9 per group). Mice received a dose of 3 or 10 mL of vaccine immune serum or 10 mL of placebo serum.
Mice were monitored for mortality (A, D, and G) for 21 days following viral challenge. Statistical significance was determined by the log rank test with a Bonferroni
correction (***p < 0.001; ****p < 0.0001). Mean weight change (B, E, and H) post-viral challenge is shown. Error bars represent SEM. Statistical significance was

(legend continued on next page)
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Figure 4. Single Dose of an mRNA LNP Vaccine Induces Protective Immunity against
POWV Challenge
C57BL/6 mice receiving one dose of the POWVsig
mRNA vaccine or a placebo vaccine were challenged 29 days later with 102 FFU of POWV
Spooner (following anti-Ifnar1 mAb treatment) (n =
10 per group).
(A) Mice were monitored for mortality for 21 days
after viral challenge. Statistical significance was
determined by log rank test (****p < 0.0001).
(B) Mean weight change after virus challenge is
shown. Error bars represent SEM. Statistical significance was determined using an ANOVA with
Sidak’s multiple comparisons test (****p < 0.0001).
(C) Serum was collected at 2 dpi and measured for
viremia by qRT-PCR. Median viral titers are
shown. Statistical significance was determined by
Mann-Whitney test (****p < 0.0001).
(D–F) Serum was collected at 2 and 21 days postchallenge and assayed for neutralization activity
by RVP assay.
(D) Neutralization titers are shown. Bars
indicate median values. Statistical significance
was determined by paired t test.
(E and F) Representative dose response curves
are shown of sera collective at day 2 (E) and day 21
(F) post-challenge.
Error bars represent ± SEM from two technical
replicates. Serum samples were collected over
two independent experiments and assayed once
each for neutralization potency.

signal sequence of JEV (JEVsig); the latter heterologous JEV signal
sequence was tested because for some flaviviruses, it results in
enhanced secretion of SVPs (Davis et al., 2001; Dowd et al.,
2016). Six-week-old WT C57BL/6 mice were immunized with
10 mg of POWVsig, JEVsig, or placebo LNPs by intramuscular inoculation, followed by a second 10 mg booster dose 28 days later
(Figure 2A). Serum was collected preboost on day 27 and postboost on day 42, and neutralizing activity was assessed by reporter virus particle (RVP) assay using the C-prM-E proteins of
the POWV lineage II strain P0375 and Raji-SIGNR cells (Mukherjee et al., 2014). RVP technology has been used extensively in the
preclinical and clinical evaluation of flavivirus vaccine candidates
(Dowd et al., 2016; Emanuel et al., 2018; Gaudinski et al., 2018;
Pardi et al., 2017; Richner et al., 2017a). Following the first
dose, the reciprocal mean titers that reduced RVP infection by
50% (50% maximal effective inhibitory concentration [EC50])
values were 13,683 ± 2,671 (n = 20) and 9,476 ± 1,271 (n = 20)
for POWVsig and JEVsig, respectively, and were not statistically
different between the two formulations (p > 0.9). Neutralization titers were boosted approximately 15-fold following the second
dose for both formulations, with EC50 values of 200,402 ±
20,414 (n = 20) for POWVsig and 225,380 ± 21,112 (n = 20) for
JEVsig. Despite the high EC50 values after the first dose, a neutralization-resistant fraction was observed for both formulations.

However, this fraction was reduced following the booster dose
from 20% to 7% (p < 0.0001 for both vaccines) (Figures 2C–2H).
A subset of post-boost sera (day 42) was tested for neutralization potency by a second assay, a focus-reduction neutralization
test (FRNT) in Vero cells. Generally, lower EC50 values were
observed by FRNT than by RVP neutralization assays, as was reported with ZIKV (Dowd et al., 2016). Nonetheless, both POWVsig
and JEVsig induced robust FRNT titers of 3,373 ± 629 (n = 17) and
3,738 ± 635 (n = 18), respectively, against POWV Spooner (Figures S1A–S1C). Furthermore, virtually no resistant fraction was
observed by FRNT, with EC90 values of 544 ± 204 (n = 17) and
392 ± 92 (n = 18) for POWVsig and JEVsig, respectively (Figures
S1A and S1C). Two other contemporary lineage II virus strains
(POWV MA5/12-#40 and FA5/12-#40), isolated from ticks
collected in Wisconsin and passaged once on BHK-21 cells,
as well as the lineage I POWV LB strain, also were neutralized
efficiently by serum from both POWVsig- and JEVsig-vaccinated
mice, as measured by FRNT (Figures S1D–S1I).
mRNA Vaccines Protect against Lethal Challenge with
Lineage I and II POWV Strains
Following the two-dose vaccination schedule, mice were challenged via subcutaneous inoculation with 102 FFU of POWV
Spooner or POWV LB at 28 days post-boost (Figure 2A).

determined using an ANOVA with Dunnett’s multiple comparisons test to compare vaccine groups to the placebo group (ns, not significant; *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001). Serum was collected at 2 dpi and measured for viremia (C, F, and I) by qRT-PCR. Bars indicate median values. Statistical significance
was determined using the Kruskal-Wallis test with Dunn’s multiple comparisons test to compare vaccine groups to the placebo group (*p < 0.05; ****p < 0.0001).
Data in each panel were collected over two independent experiments; n = 9–10 mice per group.
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Table 1. Comparison of Neutralization Titers of Serum Collected
on Day 2 or Day 21 Post-challenge
EC50 Day 2

EC50 Day 21

Day 21/Day 2 Fold Change

22213

32989

1.5

13443

45702

3.4

19565

30234

1.5

32503

25243

0.8

22913

19910

0.9

11619

11871

1.0

9921

22770

2.3

30521

29327

1.0

19043

30857

1.6

18334

18706

1.0

20008a

26761a

1.5a

Shown are the EC50 values of serum collected at day 2 or day 21 postPOWV challenge from mice receiving a single dose of POWVsig mRNA
vaccine. The fold change of day 21 EC50/day 2 EC50 is shown for each
sample. Serum samples were collected from two independent experiments.
a
Mean

POWV Spooner-challenged mice were treated one day before
infection with 0.5 mg anti-Ifnar1 mAb to achieve high mortality
rates in placebo-treated mice. Challenged mice were monitored
for survival and weight loss for 21 days, and serum samples were
collected two days post-challenge and assayed for viremia.
Following POWV Spooner challenge in anti-Ifnar1 mAb-treated
mice, and as expected, 100% of placebo-vaccinated mice succumbed to infection. In comparison, all POWVsig- and JEVsigvaccinated mice survived the challenge (Figure 3A). Furthermore, both POWVsig- and JEVsig-vaccinated mice maintained
body weight, whereas placebo-vaccinated mice lost 30%–
40% of their weight (Figure 3B). Consistent with these data,
high levels of viremia were measured in placebo-vaccinated
mice, but not in POWVsig- and JEVsig-vaccinated mice (Figure 3C). Similar results were observed following POWV LB challenge in the absence of anti-Ifnar1 mAb treatment. Whereas 80%
of placebo-vaccinated mice succumbed following LB infection,
100% of POWVsig- and JEVsig-vaccinated mice survived infection (Figure 3D). Placebo-vaccinated mice lost between 20%
and 40% of body weight, whereas POWVsig- and JEVsig-vaccinated mice maintained weight following virus challenge (Figure 3E). In addition, viremia was undetectable in POWVsig- or
JEVsig-vaccinated mice but present in placebo-vaccinated
mice (Figure 3F). Thus, both mRNA vaccine formulations protect
against lethal POWV challenge with strains from both lineages.
Passive Transfer of Serum from POWV mRNAVaccinated Animals Protects against Lethal POWV
Challenge
To assess the role of the humoral immune response in mediating protection from POWV challenge, we passively transferred serum from POWVsig-vaccinated (post-boost, day 42)
or placebo-treated mice to naive C57BL/6 mice one day before
inoculation with 102 FFU of POWV LB. Whereas 8 of 9 (89%)

mice that received 10 mL of serum from placebo-treated mice
succumbed to POWV LB challenge, 3 of 9 (33%) and 0 of 9
(0%) mice that received 3 and 10 mL of serum, respectively,
from POWVsig-vaccinated mice succumbed to viral challenge
(Figure 3G). Furthermore, the 67% and 100% of mice that survived viral challenge following passive transfer of 3 and 10 mL
of POWVsig serum, respectively, exhibited no weight loss
following viral challenge, whereas all mice receiving serum
from placebo-treated mice lost between 15% and 30% of their
body weight. Passive transfer of serum from vaccinated mice
resulted in significant reductions in viremia at 2 dpi: mice
receiving 3 mL of POWVsig serum had more than a 500-fold
reduction (p < 0.05) in viremia following challenge compared
to mice receiving serum from placebo-treated mice, and
viremia was undetectable in mice that received 10 mL of
POWVsig serum. These data indicate that the humoral immune
response to POWVsig vaccination is sufficient to protect mice
from lethal POWV challenge.
A Single Dose of POWV mRNA Vaccine Induces
Protection
We next tested whether a single dose of the POWV mRNA vaccine was sufficient for protection. For this study, we immunized
10-week-old WT C57BL/6 mice with 10 mg of POWVsig or placebo vaccines. Twenty-eight days later, mice were treated
with anti-Ifnar1 mAb and then challenged via subcutaneous
inoculation with 102 FFU of POWV Spooner. As observed previously, 100% of placebo-immunized mice succumbed to infection and lost body weight (Figures 4A and 4B). In contrast,
POWVsig-immunized mice uniformly survived challenge and
maintained body weight. Furthermore, no viremia was detected
in POWVsig-immunized mice at 2 dpi, compared to high levels in
placebo-immunized mice (Figure 4C). Serum samples were
collected on days 2 and 21 post-challenge for evaluation of
neutralization titers. EC50 values were not significantly different
between the two time points (p > 0.07) (Figure 4D), with most
mice having less than a two-fold change in titer (Table 1), indicating that little or no boost in antibody response occurred
following viral challenge in POWVsig-immunized mice. These
data suggest that one dose of mRNA vaccine was sufficient to
induce protective, if not sterilizing, immunity against POWV
challenge.
Cross-Neutralizing Activity of Serum from POWV mRNAVaccinated Mice against Other TBFVs
POWV shares 70%–78% amino acid identity of its E protein with
other mammalian TBFVs and 55%–60% identity with the seabird
TBFV clade (Figure 5A). To determine the ability of serum from
POWV-vaccinated mice to inhibit other TBFVs, we tested sera
from POWVsig- or JEVsig-vaccinated (two-dose) mice for their
capacity to inhibit TBEV, LGTV, and GGYV RVPs (Figures 5B–
5D; Figure S2). TBEV was chosen because it overlaps geographically with POWV in parts of far eastern Russia (Leonova et al.,
2009, 2017) and has a large public health impact, infecting
more than 10,000 people annually in Europe and Asia (Gritsun
et al., 2003). LGTV was selected due to its relatedness to
TBEV and prior use as a TBEV vaccine (Mandl et al., 1991).
GGYV is one of the most divergent viruses of the mammalian
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Figure 5. POWV mRNA Vaccine Induces
Cross-Neutralizing Antibodies against Other
Tick-Borne Flaviviruses
(A) Dendrogram depicting the relatedness of tickborne flavivirus E proteins (scale bar represents
0.2 amino acid substitutions per site).
(B–D) Serum samples collected post-boost in
Figure 2 were evaluated by RVP assay for
neutralizing activity against (B) TBEV (POWVsig
and JEVsig, n = 15; placebo, n = 8), (C) LGTV
(POWVsig and JEVsig, n = 13; placebo, n = 7), and
(D) GGYV (POWVsig and JEVsig, n = 15; placebo,
n = 8).
Median EC50 values are shown. Statistical significance was determined using an ANOVA with
Dunnett’s multiple comparisons test to compare
vaccine and placebo group (ns, not significant;
*p < 0.05; **p < 0.01; ****p < 0.0001). Serum
samples were collected over four independent
experiments and assayed once for neutralization
potency. See also Figures S1 and S2.

group of TBFVs (Grard et al., 2007) and thus can demonstrate the
breadth of cross-reactive response of the POWV vaccine sera.
POWV shares about 77% amino acid identity in E protein
sequence with LGTV and TBEV and 72% with GGYV. Most vaccine sera neutralized infection by RVPs bearing the E proteins of
the other TBFVs, although some samples neutralized GGYV,
whereas others did not (Figures 5B–5D). The variable neutralization of GGYV by POWV vaccine sera warrants further study
but may be due to the greater sequence dissimilarity between
the viruses (Figure 5A) and the resultant differential display of
neutralizing epitopes. Sera from POWVsig-vaccinated mice exhibited cross-neutralizing activity with mean EC50 values against
TBEV, LGTV, and GGYV of 104 ± 21 (n = 15), 215 ± 112 (n = 13),
and 113 ± 57 (n = 15), respectively. JEVsig induced similar crossneutralizing titers against TBEV (82 ± 75, n = 15), LGTV (119 ± 92,
n = 23), and GGYV (107 ± 60, n = 15).
A POWV mRNA Vaccine Protects against LGTV Infection
In Vivo
Because both POWV mRNA vaccines showed a capacity for
in vitro neutralization of other TBFVs, we tested the ability of the
POWVsig vaccine to protect against LGTV challenge in vivo. We
tested the efficacy of the POWVsig vaccine against LGTV, but
not TBEV or GGYV due to the requirement of an A-BSL4 facility
or lack of an existing challenge model, respectively. Following
the two-dose vaccination schedule (Figure 2A), mice were challenged via subcutaneous inoculation with 102 FFU of LGTV at
28 days post-boost. Because LGTV is pathogenic in Ifnar1/
mice, but not WT mice (Weber et al., 2014), we treated animals
with 0.5 mg of anti-Ifnar1 mAb one day before virus challenge.
Following LGTV challenge, 60% of placebo-treated mice lost
15% to 35% body weight, whereas only 7% of POWVsig-vacci-

3388 Cell Reports 25, 3382–3392, December 18, 2018

nated mice lost more than 10% body
weight and 87% of vaccinated mice maintained their weight (Figure 6A). POWVsigvaccinated mice were fully protected
from clinical disease, whereas 50% of
placebo-treated mice exhibited signs of paralysis, with one mouse
succumbing to LGTV challenge (Figure 6B). POWVsig-vaccinated
mice had significantly less viremia than placebo-treated mice at
2 dpi, with 6,000-fold reduction in viral titer (p < 0.0001) (Figure 6C). POWVsig-vaccinated mice also had substantially less viral
RNA in the spleen, brain, and spinal cord at 15 days post-LGTV
challenge (p < 0.0001 for all comparisons) (Figure 5D). Thus, the
POWVsig vaccine induces an immune response that can protect
against heterologous challenge with LGTV.
DISCUSSION
The frequency of epidemics caused by emerging and reemerging viruses, such as ZIKV, chikungunya virus, Ebola virus, and
Middle East respiratory syndrome coronavirus and the lack of
preparedness for these public health crises highlight the need
for the development of versatile vaccine platforms that can be
rapidly manufactured and deployed against various viral threats.
An advantage of the LNP-encapsulated modified mRNA platform is that it allows rapid development of vaccine candidates
by insertion of the desired viral mRNA sequence into the coding
region. In this study, we used the mRNA vaccine platform previously shown to be effective in mice against ZIKV (Pardi et al.,
2018; Richner et al., 2017a) to develop a countermeasure against
POWV, another emerging flavivirus (Hermance and Thangamani,
2017). Vaccination of mice with LNP-encapsulated mRNA-encoding POWV structural genes induced potently neutralizing antibody responses and protection against challenge by
POWV strains from both lineages. Furthermore, one dose of
the POWV mRNA vaccine was sufficient to induce robust immunity, because no viremia or significant anamnestic antibody
response was observed following POWV challenge.

Figure 6. POWV mRNA Vaccine Cross-Protects against LGTV Challenge
C57BL/6 mice receiving two doses of the POWVsig (n = 15) or placebo (n = 15) vaccines were challenged 4 weeks after boosting with 102 FFU of LGTV (one day
post-anti-Ifnar1 mAb treatment, 0.5 mg).
(A) Mice were monitored for weight change for 15 days following viral challenge. Mean weight change is shown. Error bars represent SEM. Statistical significance
was determined using an ANOVA with Sidak’s multiple comparisons test (**p < 0.01; ***p < 0.001; ****p < 0.0001).
(B) Mice were scored for signs of paralysis following viral challenge.
(C) Serum was collected at 2 dpi and measured for viremia by qRT-PCR.
(D) At day 15 post-viral challenge, the indicated tissues were harvested, and viral load was determined by qRT-PCR.
(C and D) Median viral titers are shown. Statistical significance was determined by Mann-Whitney test (****p < 0.0001). Data are from three independent experiments.

The antibody response induced by the POWV mRNA vaccines
broadly neutralized infection of a panel of TBFVs that included
LGTV, TBEV, and GGYV. These TBFVs differ from POWV E protein sequence by approximately 20% to 30%. The neutralization
titers were lowest against GGYV, which is the more distantly
related TBFV of those tested. Furthermore, the POWV mRNA
vaccine protected mice from disease following LGTV challenge,
indicating that this vaccine has inhibitory activity against multiple
TBFV, although the durability of the cross-protective response
warrants further testing.
Our results contrast with a prior study that observed little to
no cross-reactivity of sera from TBEV-infected or TBEV-vaccinated humans against POWV (McAuley et al., 2017). This
apparent disparity in results may have several reasons. The
antibody repertoire produced in mice versus humans in
response to TBFVs may be more cross-reactive, because
mouse and human antibody specificities to TBEV immunization can be different (Jarmer et al., 2014). Notwithstanding
these data, mouse immune ascites fluid raised against some
TBFVs (TBEV, OHFV, and KFDV) was not neutralizing against
POWV (McAuley et al., 2017). Furthermore, a separate study
evaluating a TBEV vaccine in mice observed little crossneutralization of POWV (a 1:8 antibody titer) and no cross-protection against POWV challenge in vivo (Chernokhaeva et al.,
2016). It remains possible that there is a directionality to the
cross-reactive response, such that POWV induces more

cross-reactive antibodies than TBEV or other TBFVs due to
differential display of conserved epitopes. Alternatively, the
SVPs induced by the mRNA vaccine may display more
cross-reactive epitopes than inactivated or fully infectious
TBEV virions due to differences in the arrangement of E proteins on SVPs compared to virions (Kiermayr et al., 2009;
Kuhn et al., 2015). Studies comparing the antibody repertoires
induced by LNP-mRNA vaccines to those generated after live
virus infections or inactivated virus vaccination could address
these questions. In addition, the RVP-based assay we used
to assess neutralization titers against TBEV may be more
sensitive than the plaque-reduction neutralization test
(PRNT) used by others. We observed increased sensitivity of
the RVP-based neutralization assay compared to FRNT for
POWV; however, the reciprocal result was true for LGTV in
our study.
Another explanation for the difference in cross-neutralizing
responses could be the timing of serum sampling. We evaluated the neutralization potency of sera collected 28 days
post-vaccination, whereas McAuley and colleagues tested
sera collected 3 to 204 months post-vaccination or 1.5 to
120 months post-infection (McAuley et al., 2017). Although a
previous study showed the anti-ZIKV antibody responses to
an LNP-encapsulated mRNA vaccine endure for at least five
months post-vaccination (Pardi et al., 2018), the durability
and breadth of the POWV LNP-mRNA antibody response
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warrants further study. This may apply particularly to the
cross-reactive antibody response, because anti-flavivirus antibody responses generated by long-lived plasma cells in the
memory B cell compartment in the context of West Nile virus
(WNV) infection had a more type-specific repertoire (Purtha
et al., 2011). Moreover, previous studies with ZIKV and dengue
virus (DENV) found the cross-neutralizing antibody response to
flavivirus infections is greatest during the early-convalescent
stage (<6 months) and then wanes over time (Collins et al.,
2017; Montoya et al., 2018). Chernokhaeva and colleagues
challenged mice with POWV four weeks following immunization with TBEV and observed no cross-protection (Chernokhaeva et al., 2016).
A neutralizing antibody response is an established correlate
of protection following vaccination against several flaviviruses,
including yellow fever virus, Japanese encephalitis virus, and
TBEV (Belmusto-Worn et al., 2005; Heinz et al., 2007; Mason
et al., 1973; Monath et al., 2002), and likely contributes to
protection following immunization with the POWV LNP-mRNA
vaccine. Passive transfer of serum from POWV LNP-mRNAvaccinated mice was sufficient for protection against lethal
POWV challenge. However, an LNP-mRNA ZIKV vaccine
described by Pardi and colleagues induced strong, antigenspecific T cell responses, in addition to neutralizing antibodies
(Pardi et al., 2018). Although we did not characterize the T cell
response to the POWV mRNA-LNP vaccine, because insight
into the immunodominance hierarchy and tetramer-specific
reagents are lacking, if a similar such T cell response is generated, it could contribute to protection against POWV or LGTV
challenge.
In summary, we show that the LNP-mRNA vaccine platform is
readily adaptable for development of a vaccine against another
flavivirus, POWV, with epidemic potential. This highlights the utility of this platform for development of vaccines against various
flaviviruses, from both the mosquito-borne and the tick-borne
groups, and points to the potential for optimizing adaptive immune responses so that they are broadly protective against multiple viruses.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cells
Cell lines were maintained at 37 C in the presence of 5% CO2. HEK293T cells were passaged in Dulbecco’s Modified Eagle Medium
(DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Omega Scientific) and 100 U/mL penicillin-streptomycin (PS)
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(Invitrogen). Vero cells were passaged in DMEM supplemented with 5% FBS and 100 U/mL P/S. Raji B lymphoblast cells stably expressing the C-type lectin DC-SIGNR (Raji-DCSIGNR) were cultured in RPMI 1640 medium (Invitrogen) supplemented with 7% FBS
and 100 U/mL P/S.
Mouse Studies
Experiments were approved and performed in accordance with Washington University Animal Studies Committee. C57BL/6J mice
were purchased from Jackson Laboratories and housed in a pathogen-free animal facility at Washington University in St. Louis. Both
male and female mice were vaccinated at 6 and 10 weeks of age (two dose studies) or 10 weeks of age (one dose study), and were
infected with POWV or LGTV at 14 weeks of age, or 7 weeks where indicated.
METHOD DETAILS
Generation of modified mRNA and LNP
The mRNA was synthesized in vitro using DNA-dependent T7 RNA polymerase-mediated transcription where UTP was substituted
with N1-methylpseudoUTP. A linearized DNA template was used, which incorporates 50 and 30 untranslated regions (UTRs) and includes a poly-A tail (50 -UTR: GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC; and 30 -UTR: GCUGGAGC
CUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUU
GAAUAAAGUCUGAGUGGGCGGC). The final mRNA utilized a cap 1 structure modification to increase mRNA translation efficiency.
Encoded signal sequences were from POWV prM (SGVDWTWTFLVMALMT) or JEV prM (MWLVSLAIVTACAGA) and the prM and
E genes were derived from POWV Spooner.
LNP formulations were prepared by ethanol drop nanoprecipitation on a microfluidic mixer (Precision Nanosystems). Briefly, lipids
were dissolved in ethanol at molar ratios of 50:10:38.5:1.5 (ionizable lipid: structural lipid: sterol: PEG-lipid) and mixed with mRNA in
50 mM citrate buffer, pH 4.0, at a ratio of 3:1 (aqueous:ethanol). Formulations were dialyzed against 20 mM Tris-Cl, pH 7.4, containing
sucrose (8%) in dialysis cassettes for at least 18 h. Formulations were concentrated using Amicon Ultra Centrifugal Filters (EMD Millipore) and sterile filtered through 0.22-mm filters. All formulations were tested for particle size, RNA encapsulation, and endotoxin and
were between 80 to 100 nm in size, with greater than 90% encapsulation and < 10 EU/ml of endotoxin.
Viruses
POWV lineage I strain LB (Mandl et al., 1993) was isolated originally from a human brain sample. POWV lineage II (DTV) strain Spooner
was isolated originally from adult deer ticks (Ebel et al., 1999). LGTV strain E5 was derived from strain TP21 (Campbell and Pletnev,
2000). POWV LB, POWV Spooner, and LGTV were obtained from World Reference Center for Emerging Viruses and Arboviruses (R.
Tesh and S. Weaver, University of Texas Medical Branch). POWV strains MA5/12-#40 and FA5/12-#40 were isolated from ticks
collected in Wisconsin as described (Brackney et al., 2008). Virus was isolated by inoculating BHK-21 cells with 100 ml of the homogenate of POWV RNA positive ticks and harvesting virus supernatant when CPE was approximately 50%. Virus stocks were
propagated on Vero cells and used at passage 3 (POWV LB and POWV Spooner) or passage 4 (LGTV). Viral titer was determined
by focus-forming assay (FFA) on Vero cells as described previously (Brien et al., 2013) with the following modifications: FFA infections
were fixed after 72 (POWV LB and POWV Spooner) or 48 (LGTV) h and stained with ZV-13, a flavivirus cross-reactive mouse mAb
(Zhao et al., 2016).
Plasmids
The plasmid encoding a sub-genomic replicon of the WNV lineage II strain 956 that expresses GFP (WNVrepG/Z) has been reported
(Ansarah-Sobrinho et al., 2008; Pierson et al., 2006). Plasmids that express the C-prM-E structural genes of POWV strain P0375
(GenBank accession number KU886216), TBEV strain Neudoerfl (GenBank accession number U27495), LGTV strain TP21 (GenBank
accession number NC_003690), and GGYV strain Macquarie Island (GenBank: DQ235145) were cloned into the expression vector
pcDNA3.1 (Invitrogen, Carlsbad, CA). All plasmid propagation and cloning procedures were performed using Stbl2 bacteria grown at
30 C (Invitrogen, Carlsbad, CA).
Reporter virus particles
Reporter virus particles (RVPs) were produced by the genetic complementation of a DNA-launched, sub-genomic replicon with a
C-prM-E expression plasmid, as described previously (Ansarah-Sobrinho et al., 2008; Pierson et al., 2006). Briefly, pre-plated
HEK293T cells were co-transfected with WNVrepG/Z, a WNV replicon expressing a GFP reporter gene, and the C-prM-E expression plasmids described above using FugeneHD (Promega) in accordance with the manufacturer’s instructions. Transfected cells were incubated
at 37 C, and supernatant was harvested at 48 h post-transfection, filtered using a 0.22 mm syringe filter, and stored at 80 C. The infectious titer of RVPs was assayed using Raji-DC-SIGNR cells, as described previously (Ansarah-Sobrinho et al., 2008; Pierson et al., 2006).
Neutralization assays
(a) RVP neutralization assays were performed as described (Mukherjee et al., 2014). Briefly, RVP stocks were diluted and incubated
with serial dilutions of serum for 1 h at 37 C prior to the addition of Raji-DCSIGNR cells. Infections were carried out at 37 C for 48 h,
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and infectivity was scored as the percentage of GFP-expressing cells determined by flow cytometry. (b) Focus-reduction neutralization test (FRNT) experiments were performed as described for other flaviviruses (Richner et al., 2017a). Briefly, serial dilutions
of serum were incubated with 200 FFU of POWV Spooner for 1 h at 37 C. Serum/virus mixtures were added to Vero cell monolayers
and incubated for 1 h at 37 C prior to the addition of 1% (w/v) methycellulose in MEM. FRNT experiments proceeded as described for
FFA experiments above. For both RVP neutralization assays and FRNT, antibody-dose response curves were analyzed using nonlinear regression analysis (with a variable slope) (GraphPad Software). Data are expressed as the serum dilution required to reduce
infection by half (EC50) or, where indicated, by 90% (EC90). To obtain EC50 values when a resistant fraction was present, the bottom
of the curve was constrained to zero.
Mouse experiments
Immunizations with the LNP mRNA vaccines were administered via intramuscular injection in a 50 mL volume. For passive transfer
studies, serum was diluted in PBS and administered to mice via intraperitoneal injection in a 100 mL total volume; mice received a
dose of 3 mL or 10 mL of serum from POWVsig-vaccinated mice or 10 mL of serum from placebo-treated mice. Viral infections with
POWV or LGTV were performed via subcutaneous inoculation in the footpad with 102 FFU of virus. For LGTV and POWV Spooner
challenge, 0.5 mg of anti-Ifnar1 blocking mAb MAR1-5A3 (Sheehan et al., 2006) was administered one day prior to infection via intraperitoneal injection. Animals were monitored for mortality, weight loss, and clinical score. To evaluate clinical disease following
POWV infection, mice were assigned to one of the following categories each day: (A) no disease, (B) ruffled fur, (C) ruffled fur with
hunched posture, (D) lethargy or decreased scurrying activity, (E) sick with slow to no movement, or (F) moribund or dead; moribund
mice were euthanized. To evaluate clinical disease following LGTV challenge, cages were blinded and mice were assigned to one of
the following categories each day: (A) no disease, (B) partial hindlimb paralysis, (C) complete paralysis of one hindlimb, (D) complete
paralysis of both hindlimbs, or (E) moribund or dead; moribund mice were euthanized.
Measurement of viral burden
On indicated days post-infection, mice were sacrificed and organs were collected following extensive perfusion with PBS. Organs
were weighed and homogenized using a MagNA Lyser (Roche). Viral RNA from homogenized organs or serum was isolated using the
MagMAX Viral RNA Isolation Kit (ThermoFisher) and measured by TaqMan one-step quantitative reverse-transcription PCR (RTqPCR) on an ABI 7500 Fast Instrument. Viral RNA levels are expressed on a log10 scale as viral RNA equivalents per gram or milliliter
after comparison with a standard curve produced using serial 10-fold dilutions of viral RNA from known quantities of infectious virus in
order to estimate viral burden. POWV Spooner primers, which have been described (Platt et al., 2018), were 50 - GCAGCACCATAGG
TAGAATGT-30 , 50 - CCACCCACTGAACCAAAGT-30 , and probe 50 -/56-FAM/ TCTCAGTGG/Zen/TTGGAGAACACGCAT/3IABkFQ-30 .
POWV LB primers were 50 - GGCTGCAAATGAGACCAATTC-30 , 50 - CAGCGACACATCTCCATAGTC-30 , and probe 50 -/56-FAM/
TGGCATCCG/Zen/AGAAAGTGATCCTGC/3IABkFQ/-30 . LGTV primers were 50 - GGAACTAGGCCTTGCAGAAT-30 , 50 - TGTT
CTCCATTGTCGGGTTAG-30 , and probe 50 -/56-FAM/TGAGGTTAA/Zen/CGTGGCCATGCTCAT/3IABkF-3 0 .
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed using Prism software Version 7.0 for Mac OS X (GraphPad Software). Log EC50 or Log EC90
values were compared by one-way ANOVA followed by Tukey’s multiple comparisons test. For survival analysis, Kaplan-Meier
curves were plotted and analyzed by the log rank test with a Bonferroni correction for multiple comparisons. Weight loss experiments
were compared by an ANOVA followed by Dunnett’s multiple comparisons test to compare vaccine groups to the placebo group, or
by Sidak’s multiple comparisons test when two groups were compared. Viremia and viral burden in tissues were compared by MannWhitney test when two groups were compared, or by Kruskal Wallis test followed by Dunn’s multiple comparisons test when more
than two groups were compared.

Cell Reports 25, 3382–3392.e1–e3, December 18, 2018 e3

Cell Reports, Volume 25

Supplemental Information

An mRNA Vaccine Protects Mice against Multiple
Tick-Transmitted Flavivirus Infections
Laura A. VanBlargan, Sunny Himansu, Bryant M. Foreman, Gregory D. Ebel, Theodore C.
Pierson, and Michael S. Diamond

5

3
2

0

0

POWV MA5/12-#40, EC50
5

2
1

4

si

g

3

2

5
4
3
2

6

5

4

3

2

1

0

Log10 serum dilution

POWV LB, EC50
5

****
****

4
3
2

V

si

g
pl
ac
eb
o

JE

si

g

1

PO
W
V

si

g
pl
ac
eb
o

g
si

V
JE

0

0

****
****

1

PO
W
V

1

POWV FA5/12 - #40, EC50

Log10 EC50

3

5

Log10 serum dilution

****
****

4

6

si

1

g
pl
ac
eb
o

2

placebo

g

3

Log10 serum dilution

JEVsig

50

V

4

placebo

POWVsig

100

si

5

50

150

JE

6

JEVsig

Relative infectivity

placebo

50

POWVsig

Log10 EC50

JEVsig

100

PO
W
V

POWVsig

Relative infectivity

Relative infectivity

200

150

100

Log10 EC50

POWV LB

POWV FA5/12 - #40

POWV MA5/12-#40
150

0

si

si

PO
W
V

Log10 serum dilution

PO
W
V

0

g
pl
ac
eb
o

1

g

2

si

3

V

4

JE

5

2
1

1

6

3

g
pl
ac
eb
o

placebo

****
****

4

V

JEVsig
50

4

JE

POWVsig

5

****
****
Log10 EC90

100

Log10 EC50

Relative infectivity

150

0

POWV Spooner, EC90

POWV Spooner, EC50

POWV Spooner

Figure S1. Related to Figure 2. POWVsig and JEVsig vaccines induce neutralizing antibodies
as measured by FRNT. Serum samples collected post-boost (as described in Fig 2) were
assayed for neutralizing activity by FRNT using (A-C) POWV Spooner (lineage II), (D-E)
POWV MA5/12-#40 (lineage II), (F-G) POWV FA5/12-#40 (lineage II), and (H-I) POWV LB
(lineage I). (A, D, F, and H) Representative dose response curves are shown for the indicated
vaccines. (B, E, G, and I) The neutralization titers (EC50 values) are shown. (C) EC90 values
are shown. (B, C, E, G, and I) Error bars represent SD. Statistical significance was determined
using an ANOVA with a Tukey’s multiple comparisons test (****, P < 0.0001). Data are from
two (D-I) or three (A-C) independent experiments.
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Figure S2. Related to Figure 5. Cross-reactivity of sera from POWV-vaccinated mice. (A-F)
Representative dose-response curves from neutralization assays described in Figure 5 are shown.
(G-H) Serum samples collected post-boost (as described in Fig 2) were assayed for neutralizing
activity by FRNT using LGTV. (G) Representative dose response curves are shown for the
indicated vaccines. (H) The neutralization titers (EC50 values) are shown. Statistical significance
was determined using an ANOVA with a Tukey’s multiple comparisons test (****, P < 0.0001).
Data are from two independent experiments.

